Ketone Body Metabolism

Ketone bodies are water-soluble, lipid-derived fuels synthesised exclusively in liver mitochondria and exported to extrahepatic tissues during fasting, starvation, prolonged exercise, and uncontrolled diabetes. This topic is a conceptual NEET PG favourite because it ties together enzyme localisation, the liver–peripheral tissue paradox, and the clinical spectrum of ketosis versus ketoacidosis.

Definition and Classification

The three "ketone bodies" are:

Ketone body	Chemistry	% in blood (normal/DKA)	Notes
Acetoacetate (AcAc)	True ketone (β-keto acid)	Minor fraction	The parent compound; can be reversibly reduced
β-Hydroxybutyrate (BHB / 3-HB)	NOT a true ketone (it is a hydroxy acid)	Predominant (ratio rises in severe acidosis)	Quantitatively the major circulating species
Acetone	True ketone	Trace	Volatile, non-metabolisable, exhaled (fruity breath)

High-yield: β-Hydroxybutyrate is the most abundant ketone body in blood, yet chemically it is not a ketone (no keto group — it has a hydroxyl). Acetone is the chemically simplest but is metabolically a dead end — it is excreted via lungs and urine.

The interconversion is governed by the mitochondrial redox state:

AcAc + NADH + H⁺ ⇌ β-Hydroxybutyrate + NAD⁺ (enzyme: β-hydroxybutyrate dehydrogenase)

A high NADH/NAD⁺ ratio (as in alcoholism or severe DKA) pushes the equilibrium toward BHB. This is clinically crucial — the nitroprusside (Rothera) test and urine dipstick detect acetoacetate and acetone but NOT BHB, so severe ketoacidosis can be underestimated when most ketone is in the BHB form.

Site, Substrate, and Enzymes of Ketogenesis

• Site: Liver mitochondrial matrix (hepatocytes). Ketogenesis is essentially confined to the liver (small amounts in renal cortex).
• Substrate: Acetyl-CoA, derived chiefly from accelerated β-oxidation of fatty acids when carbohydrate is scarce.
• Trigger setting: Low insulin / high glucagon → lipolysis → ↑ free fatty acids → ↑ hepatic β-oxidation → acetyl-CoA accumulates faster than the TCA cycle can handle (oxaloacetate is diverted to gluconeogenesis), so acetyl-CoA is shunted into ketogenesis.

Stepwise pathway (ketogenesis)

1. 2 Acetyl-CoA → Acetoacetyl-CoA — enzyme thiolase (acetyl-CoA acetyltransferase); releases 1 CoA.
2. Acetoacetyl-CoA + Acetyl-CoA → HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) — enzyme HMG-CoA synthase (mitochondrial isoform) — the rate-limiting / committed step.
3. HMG-CoA → Acetoacetate + Acetyl-CoA — enzyme HMG-CoA lyase — the diagnostic ketogenic step.
4. Acetoacetate → β-Hydroxybutyrate — enzyme β-HB dehydrogenase (NADH-dependent), OR
5. Acetoacetate → Acetone + CO₂ — by spontaneous (non-enzymatic) decarboxylation when AcAc is high.

Flow: Fatty acids → β-oxidation → Acetyl-CoA → (thiolase) → Acetoacetyl-CoA → (HMG-CoA synthase, RLS) → HMG-CoA → (HMG-CoA lyase) → Acetoacetate → BHB / acetone.

High-yield: The mitochondrial HMG-CoA synthase is the rate-limiting enzyme of ketogenesis. Do not confuse it with cytosolic HMG-CoA synthase, which feeds cholesterol synthesis. Both make HMG-CoA but in different compartments for different fates.

High-yield: HMG-CoA lyase is shared between ketogenesis and leucine catabolism. Its deficiency causes hypoketotic hypoglycaemia with metabolic acidosis and hyperammonaemia — an inborn error worth remembering.

Mnemonic — "Some Lazy Liver Makes Ketones": Synthase (HMG-CoA) is rate-limiting, Lyase generates acetoacetate, Liver is the factory, Mitochondria is the site, Ketones are exported.

Ketolysis — Utilisation in Peripheral Tissues

The liver cannot use the ketone bodies it makes — this is the central paradox.

• Reason: Hepatocytes lack the enzyme thiophorase, i.e. succinyl-CoA:acetoacetate CoA transferase (SCOT, also called OXCT1), which is required to reactivate acetoacetate.
• Extrahepatic tissues (cardiac muscle, skeletal muscle, renal cortex, and — after adaptation — brain) possess SCOT and oxidise ketone bodies readily.

Stepwise ketolysis

1. β-Hydroxybutyrate → Acetoacetate (β-HB dehydrogenase, regenerating NADH).
2. Acetoacetate + Succinyl-CoA → Acetoacetyl-CoA + Succinate — enzyme thiophorase (SCOT) — the key activating step absent in liver.
3. Acetoacetyl-CoA + CoA → 2 Acetyl-CoA (thiolase).
4. Acetyl-CoA → TCA cycle → ATP.

High-yield: Liver lacks thiophorase (SCOT) → cannot oxidise ketones → exports them. RBCs (no mitochondria) and the liver cannot use ketone bodies. Brain uses glucose normally but adapts to use ketones in prolonged starvation, reducing its glucose requirement from ~120 g/day to ~40 g/day.

Tissue	Can OXIDISE ketones?	Reason
Liver	No	Lacks thiophorase (SCOT); it is the producer
RBC	No	No mitochondria
Cardiac & skeletal muscle	Yes (heart prefers them)	Has SCOT
Renal cortex	Yes	Has SCOT
Brain	Yes, after adaptation (starvation)	Induces SCOT/transport over days

Physiology and Regulation

The master switch is the insulin : glucagon ratio.

• Fed state (high insulin): Lipolysis suppressed; malonyl-CoA is high (from active fatty-acid synthesis); malonyl-CoA inhibits CPT-1, blocking fatty-acyl entry into mitochondria → β-oxidation off → ketogenesis off.
• Fasting/starvation (low insulin, high glucagon): Lipolysis active → ↑ FFA; malonyl-CoA low → CPT-1 active → ↑ β-oxidation → ↑ acetyl-CoA. Oxaloacetate is consumed by gluconeogenesis, so acetyl-CoA cannot enter TCA efficiently and is diverted to ketones.

High-yield: CPT-1 (carnitine palmitoyltransferase-1) is the gatekeeper of mitochondrial fatty-acid entry and the overall control point that determines whether ketogenesis proceeds. Malonyl-CoA is its physiological inhibitor — the link between fatty-acid synthesis and ketogenesis.

High-yield: "Fat burns in the flame of carbohydrate" — when oxaloacetate is depleted (gluconeogenesis), acetyl-CoA cannot be fully oxidised in the TCA cycle and overflows into ketone bodies.

Caloric value and brain fuel

Ketone bodies are an efficient, transportable form of acetyl-CoA. During prolonged starvation, BHB and acetoacetate supply up to ~60–70% of the brain's energy, sparing protein (muscle) breakdown and limiting gluconeogenic amino-acid drain — a key survival adaptation.

Clinical Spectrum of Ketosis

Feature	Physiological (starvation/fasting) ketosis	Diabetic ketoacidosis (DKA)	Alcoholic ketoacidosis
Underlying defect	Carbohydrate deprivation, insulin present	Absolute insulin deficiency (T1DM)	Glycogen depletion + high NADH
Glucose	Low–normal	High (>250 mg/dL typically)	Low/normal/mildly high
Magnitude of ketosis	Mild–moderate	Severe	Moderate–severe
Acidosis	Usually compensated	High anion-gap metabolic acidosis	High anion-gap
Predominant ketone	AcAc/BHB balanced	BHB markedly raised	BHB markedly raised (high NADH)
Treatment	Refeed	Insulin + IV fluids + K⁺	IV dextrose + saline + thiamine

Why DKA is dangerous

In type 1 diabetes, absolute insulin lack removes the brake on lipolysis and ketogenesis simultaneously with unrestrained gluconeogenesis. Ketone acids dissociate, consuming bicarbonate and producing a high anion-gap metabolic acidosis. Clinically: polyuria, dehydration, Kussmaul respiration (deep sighing breathing to blow off CO₂), fruity (acetone) breath, abdominal pain, drowsiness → coma.

High-yield: In DKA the urine/serum nitroprusside test reacts with acetoacetate, not BHB. Because the high NADH state of DKA shifts ketones toward BHB, the dipstick may underestimate severity initially and may paradoxically appear to worsen during treatment as BHB is converted back to AcAc. Therefore, direct serum β-hydroxybutyrate measurement is the preferred investigation for diagnosing and monitoring DKA.

High-yield: Type 2 diabetics are relatively protected from DKA because residual insulin suppresses ketogenesis; they more often develop hyperosmolar hyperglycaemic state (HHS) with minimal ketosis. (SGLT2-inhibitor–associated euglycaemic DKA is the important modern exception.)

Diagnosis and Investigation of Choice

• Investigation of choice for ketoacidosis severity/monitoring: Serum β-hydroxybutyrate (point-of-care BHB meters). A capillary BHB ≥3.0 mmol/L strongly supports significant ketosis/DKA.
• Bedside screen: Urine ketone dipstick (nitroprusside) — detects AcAc/acetone only; useful but limited.
• DKA biochemical triad:
  1. Hyperglycaemia (glucose >250 mg/dL, though euglycaemic DKA exists)
  2. Ketonaemia/ketonuria (BHB ≥3 mmol/L)
  3. High anion-gap metabolic acidosis (pH <7.3 and/or HCO₃⁻ <18 mEq/L; anion gap >12)
• Anion gap = Na⁺ − (Cl⁻ + HCO₃⁻); raised by the unmeasured ketoacid anions.

Management / Drug of Choice

• DKA management flow: Fluids (isotonic saline) → Insulin (regular insulin IV infusion) → Potassium replacement → correct precipitant.
• Insulin is the definitive agent: it switches off lipolysis and ketogenesis and promotes glucose uptake. Start IV regular insulin once potassium is ≥3.3 mEq/L (insulin drives K⁺ intracellularly and can precipitate fatal hypokalaemia).
• Potassium: Total body K⁺ is depleted even when serum K⁺ looks normal/high (acidosis shifts K⁺ out of cells); replace early.
• Bicarbonate: Reserved for severe acidaemia (pH <6.9) — not routine.
• Dextrose added when glucose falls to ~200 mg/dL to continue insulin (clearing ketones) without hypoglycaemia.
• Alcoholic ketoacidosis: IV dextrose + saline + thiamine (thiamine before glucose to prevent Wernicke). Physiological starvation ketosis simply needs refeeding with carbohydrate.

Complications

• DKA: Cerebral oedema (especially children — feared complication), hypokalaemia, hypoglycaemia (over-treatment), aspiration, acute kidney injury, thromboembolism.
• Chronic/recurrent ketosis: Growth and developmental issues in inborn errors.
• Inborn errors of ketone metabolism:
  • HMG-CoA lyase deficiency → hypoketotic hypoglycaemia, metabolic acidosis, hyperammonaemia.
  • SCOT (thiophorase) deficiency → recurrent ketoacidosis with persistent ketosis even when fed (cannot utilise ketones).
  • β-ketothiolase (T2/ACAT1) deficiency → episodic ketoacidosis.

Key Differentials of High-Anion-Gap Metabolic Acidosis

Use the classic mnemonic "MUDPILES" (or modern GOLD MARK):

• Methanol, Uraemia, DKA, Propylene glycol/Paraldehyde, Iron/Isoniazid, Lactic acidosis, Ethylene glycol, Salicylates.

Distinguish ketoacidosis from lactic acidosis (raised lactate, ketones negative) and toxic alcohol ingestion (osmolar gap raised). Within ketoacidoses, separate diabetic (hyperglycaemic), alcoholic (history + low/normal glucose), and starvation (mild, glucose low) using glucose and history.

Recently asked / exam angle

• "Most abundant ketone body in blood" → β-hydroxybutyrate. "Which is not a true ketone?" → β-hydroxybutyrate.
• "Rate-limiting enzyme of ketogenesis" → mitochondrial HMG-CoA synthase.
• "Enzyme deficient in liver that prevents it from using ketone bodies" → thiophorase (SCOT / succinyl-CoA:acetoacetate CoA transferase).
• "Ketone body not detected by nitroprusside/Rothera test" → β-hydroxybutyrate; hence serum BHB preferred for monitoring DKA.
• "Tissues that cannot use ketone bodies" → liver and RBC.
• "Source of acetone" → spontaneous (non-enzymatic) decarboxylation of acetoacetate; gives fruity breath.
• Image/clinical vignette: Kussmaul breathing + fruity breath + high glucose + high anion gap → DKA; first step = IV fluids, then insulin, watch potassium.
• "Brain's major fuel in prolonged starvation" → ketone bodies.
• "Enzyme shared by ketogenesis and leucine degradation" → HMG-CoA lyase.
• Pharma crossover: SGLT2 inhibitors → euglycaemic DKA (high-yield clinical pearl).

Rapid revision

1. Ketone bodies = acetoacetate, β-hydroxybutyrate, acetone; made only in liver mitochondria.
2. β-Hydroxybutyrate is the most abundant and is not a true ketone.
3. Acetone is non-metabolisable, exhaled → fruity breath.
4. Rate-limiting enzyme = mitochondrial HMG-CoA synthase; diagnostic step = HMG-CoA lyase.
5. Liver cannot use ketones because it lacks thiophorase (SCOT); RBC can't either (no mitochondria).
6. CPT-1 (inhibited by malonyl-CoA) gates fatty-acid entry → controls ketogenesis.
7. Driven by low insulin / high glucagon; "fat burns in the flame of carbohydrate" (oxaloacetate depletion).
8. Brain uses ketones in prolonged starvation, sparing protein.
9. Nitroprusside/Rothera test detects AcAc + acetone, NOT BHB — can underestimate DKA.
10. Serum BHB is the investigation of choice for DKA severity/monitoring.
11. DKA triad: hyperglycaemia + ketonaemia + high-anion-gap acidosis; treat with fluids → insulin → potassium.
12. HMG-CoA lyase deficiency → hypoketotic hypoglycaemia; SCOT deficiency → ketosis even when fed.